Potential Pharmacological Options and New Avenues Using Inhaled Curcumin Nanoformulations for Treatment of Post-COVID-19 Fibrosis
Abstract
Edward Christopher Yo, Marcello Mikhael Kadharusman, Adrian Prasetya Karman, Melva Louisa, Wawaimuli Arozal.
Coronavirus disease (COVID-19) is a highly infectious disease caused by SARS-CoV-2 that may lead to adverse respiratory problems and death. As of January 17th, 2021, it has transformed into a global health crisis with 93,194,922 reported cases and 2.2% case fatality rate. Severe form of COVID-19 may progress into acute respiratory distress syndrome (ARDS), which in turn leads to pulmonary fibrosis. This review aims to investigate the potential use of anti-inflammatory and antifibrotic drugs as well as inhaled curcumin nanoformulations for post-ARDS fibrosis. Anti-inflammatory and antifibrotic drugs can inhibit certain pathways in the development of post-ARDS fibrosis, but there are serious limitations in their use. Since transforming growth factor-β (TGF-β) is the most important pathway in fibrosis development and is up-regulated in SARS-CoV-2 infection, antifibrotic agents that target it may be an alternative treatment. This property can be found in curcumin. Complexing curcumin with nanoparticles has proven to be safe, cost-effective, and enhances its pharmacodynamic action. Unlike current drugs, curcumin nanoformulations can be generated as inhaled aerosol and given to COVID-19 ARDS patients receiving mechanical ventilation. Future research should clarify the recommended dosing and timing of curcumin aerosol delivery, its safety and efficacy, as well as its long-term effects in the lungs.
| How to Cite this Article |
| Pubmed Style Yo EC, Kadharusman MM, Karman AP, Louisa M, Arozal W. Potential Pharmacological Options and New Avenues Using Inhaled Curcumin Nanoformulations for Treatment of Post-COVID-19 Fibrosis. SRP. 2021; 12(1): 1119-1128. doi:10.31838/srp.2021.1.155 Web Style Yo EC, Kadharusman MM, Karman AP, Louisa M, Arozal W. Potential Pharmacological Options and New Avenues Using Inhaled Curcumin Nanoformulations for Treatment of Post-COVID-19 Fibrosis. http://www.sysrevpharm.org/?mno=47944 [Access: March 31, 2021]. doi:10.31838/srp.2021.1.155 AMA (American Medical Association) Style Yo EC, Kadharusman MM, Karman AP, Louisa M, Arozal W. Potential Pharmacological Options and New Avenues Using Inhaled Curcumin Nanoformulations for Treatment of Post-COVID-19 Fibrosis. SRP. 2021; 12(1): 1119-1128. doi:10.31838/srp.2021.1.155 Vancouver/ICMJE Style Yo EC, Kadharusman MM, Karman AP, Louisa M, Arozal W. Potential Pharmacological Options and New Avenues Using Inhaled Curcumin Nanoformulations for Treatment of Post-COVID-19 Fibrosis. SRP. (2021), [cited March 31, 2021]; 12(1): 1119-1128. doi:10.31838/srp.2021.1.155 Harvard Style Yo, E. C., Kadharusman, . M. M., Karman, . A. P., Louisa, . M. & Arozal, . W. (2021) Potential Pharmacological Options and New Avenues Using Inhaled Curcumin Nanoformulations for Treatment of Post-COVID-19 Fibrosis. SRP, 12 (1), 1119-1128. doi:10.31838/srp.2021.1.155 Turabian Style Yo, Edward Christopher, Marcello Mikhael Kadharusman, Adrian Prasetya Karman, Melva Louisa, and Wawaimuli Arozal. 2021. Potential Pharmacological Options and New Avenues Using Inhaled Curcumin Nanoformulations for Treatment of Post-COVID-19 Fibrosis. Systematic Reviews in Pharmacy, 12 (1), 1119-1128. doi:10.31838/srp.2021.1.155 Chicago Style Yo, Edward Christopher, Marcello Mikhael Kadharusman, Adrian Prasetya Karman, Melva Louisa, and Wawaimuli Arozal. "Potential Pharmacological Options and New Avenues Using Inhaled Curcumin Nanoformulations for Treatment of Post-COVID-19 Fibrosis." Systematic Reviews in Pharmacy 12 (2021), 1119-1128. doi:10.31838/srp.2021.1.155 MLA (The Modern Language Association) Style Yo, Edward Christopher, Marcello Mikhael Kadharusman, Adrian Prasetya Karman, Melva Louisa, and Wawaimuli Arozal. "Potential Pharmacological Options and New Avenues Using Inhaled Curcumin Nanoformulations for Treatment of Post-COVID-19 Fibrosis." Systematic Reviews in Pharmacy 12.1 (2021), 1119-1128. Print. doi:10.31838/srp.2021.1.155 APA (American Psychological Association) Style Yo, E. C., Kadharusman, . M. M., Karman, . A. P., Louisa, . M. & Arozal, . W. (2021) Potential Pharmacological Options and New Avenues Using Inhaled Curcumin Nanoformulations for Treatment of Post-COVID-19 Fibrosis. Systematic Reviews in Pharmacy, 12 (1), 1119-1128. doi:10.31838/srp.2021.1.155 |
Abstract
PDF
How to cite this article
Related Records